Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Section 2 of 6

Executive summary

12 evidence topics · 68 sources

Clinical benefits of Darovasertib

Burden of metastatic uveal melanoma

Summary: epidemiology and the HLA-A∗02:01-negative share

From 1975 to 2020, the mean age-adjusted incidence of primary uveal melanoma in the United States was 5.6 per million population (6.3 per million in males and 5.0 in females), 98% of cases were in the white race, and the median age at diagnosis was 63 years. A second analysis of 37,917 cases reported an overall age-adjusted incidence of 5.54 per million, highest in non-Hispanic whites (6.87 per million) and in those aged 75 to 79 years; the National Cancer Institute gives approximately 4.3 new cases per million. Siegel et al. and the American Cancer Society estimate about 3,200 new cancers of the eye and orbit, mainly melanomas, in the United States in 2026, and Castle Biosciences estimates that approximately 2,000 patients in the U.S. are diagnosed with uveal melanoma each year. The European Medicines Agency estimated a prevalence of 0.88 per 10,000 persons in the European Union. No source states the U.S. prevalence of metastatic uveal melanoma.

Fewer than 2% of patients present with detectable metastases at diagnosis of the primary tumor according to Piperno-Neumann et al., 2% to 3% according to the National Cancer Institute, and 69 of 3610 (1.9%) in one cohort. Local therapy controls the primary tumor in more than 90% of cases, but up to 50% of patients develop metastases, mainly in the liver (90%). After treatment of choroidal melanoma, 5- and 10-year cumulative metastasis rates were 25% and 34%, and in a separate cohort the median time from initial treatment of the tumor to metastasis was 3.45 years.

Approximately 45% of people in the United States and Europe are HLA-A∗02:01-positive, and 40% to 50% of the European population express HLA-A∗02:01. In a trial of tebentafusp, HLA-A∗02:01-negative patients comprised 49% of individuals prescreened. In a deidentified multimodal database of 219 adults diagnosed with metastatic uveal melanoma from 2019 to 2025, HLA-A∗02:01 status was positive in 42.0%, negative in 42.9%, and unknown in 15.1%. Among Brazilians tested, HLA-A∗02:01 positivity by race ranged from 17.5% in black to 22.8% in indigenous individuals, lower than in North Americans and Europeans. HLA-A∗02:01 occurs at a higher frequency in uveal melanoma patients than in the general population.

Summary: natural history, survival, and mortality

Five-year relative survival for all uveal melanoma in the United States was 82.8% from 1975 to 2016; a second analysis reported 5- and 10-year relative survival of 83.3% and 73.9%, “with worse outcomes in metastatic disease”. Siegel et al. estimate 530 U.S. deaths from eye and orbit cancer in 2026. The cumulative probability of melanoma metastatic death was 0.241 at 10 years and 0.301 at 30 years, with deaths from melanoma rare beyond 20 years, and uveal melanoma-related mortality was 31% by 5 years and 52% by 35 years in a second cohort.

Following the report of metastasis from choroidal melanoma, the death rate was 80% at 1 year and 92% at 2 years, and only 8 patients survived 5 or more years. In a single cohort, median survival after metastasis was 3.9 months overall, 6.3 months with treatment, and 1.7 months without. In individual patient data from 29 trials published from 2000 to 2016, median progression-free survival was 3.3 months, the 6-month progression-free survival rate 27%, median overall survival 10.2 months, and 1-year overall survival 43%. Across 78 articles with 2494 patients, median overall survival was 1.07 years, and meta-analyses place survival beyond 5 years at an estimated 2%. With active treatment, median overall survival in one cohort was 18, 6.9, and 1.9 months in working formulation stage IVa, IVb, and IVc, respectively. Elevated lactate dehydrogenase and elevated alkaline phosphatase were the strongest prognostic factors for shorter overall survival; in another cohort, a lactate dehydrogenase level above 500 U/L carried a hazard ratio of 9.0 and liver metastases a hazard ratio of 2.09. Weinberger et al. state that it will be several years before the impact of newer systemic therapies is captured in the SEER database.

Summary: humanistic burden

In qualitative interviews with seventeen patients and 16 clinicians, most patients placed greater emphasis on the emotional than the physical impacts of disease and treatment, centred on the “existential threat posed by metastatic disease”, and described treatment burden from time commitment, travel, hospitalisation, and expense; of the treatments received, tebentafusp “conferred the heaviest inconvenience and symptom burden”. Several patients reduced or ceased employment. Anxiety increased in the days before a test until results were received, with waits of 1 day to 3 weeks. Among 475 participants followed for up to 84 months after treatment, 17.5% showed consistently elevated anxiety and 10.9% consistently elevated depression, while in a series of 708 survivors no prognostic group reported anxiety, depression, or quality of life scores beyond general population norms.

In the IMCgp100-202 trial (NCT03070392), mean EORTC QLQ-C30 global health status at baseline was 76.108 with tebentafusp and 74.872 with investigator's choice, and the mean change at end of treatment was -10.417 and -10.539; the mean change in the EQ-5D visual analogue scale at end of treatment was -10.1 and -11.7. In a randomized phase 2 trial of selumetinib versus chemotherapy (118 participants reporting), mean health-related quality of life scores did not differ significantly at any of the three time points. After percutaneous hepatic perfusion with melphalan (M-PHP), scores declined on day 2/3 and 12 of 15 scores returned to baseline by day 21 in 24 participants, and in 20 participants the median FACT-G score fell from 101.8 at baseline to 85 on day 1 and recovered to 100.3 by day 28. In the SCANDIUM trial, EQ-5D-3L health utility was 0.87 with isolated hepatic perfusion versus 0.70 with control at 6 months and 0.88 versus 0.66 at 12 months; the difference was not significant after adjustment for baseline utility.

Summary: economic burden and testing costs

In the MarketScan Commercial, Medicare, and Multi-State Medicaid databases, 471 patients with metastatic uveal melanoma (47% commercially insured, 43% Medicare, 10% Medicaid) had mean healthcare costs of $29,187 per patient per month (SD $46,089), comprising inpatient costs of $6,502 (including $4,049 for ICU admissions), outpatient medical services of $20,555, and outpatient pharmacy costs of $2,131. Among commercial and Medicare patients, mean all-cause costs per patient per month were highest with tebentafusp ($93,805); adverse event-related costs were also highest with tebentafusp ($6,746) and formed the largest share of total costs with chemotherapy (12.9%). Only half of these patients received any systemic treatment, and 19% received liver directed therapy. In HES data from April 2012 to June 2016, inpatient admissions for metastatic uveal melanoma cost NHSE £2.5 million (mean £6,084 per patient), the cohort attended 3,618 outpatient appointments and had 669 A&E visits, and 28% of patients were treated 40 km or more from home. Tebentafusp requires hospitalisation at commencement: patients treated with tebentafusp (TEBE) at one center received a median of 4 inpatient doses, and another cohort had a median of 3 cumulative inpatient nights for doses 1 to 3.

Patients and families bear travel and treatment costs: 50% of participants in the Ocumel Canada survey required some assistance with travel costs, participants in a qualitative study described worry about self-funding treatment and the financial burden on their family, and respondents with metastatic disease reported occasional dependence on a spouse, partner, child, or caregiver.

The Kentucky Department for Medicaid Services 2026 fee schedule pays $169.90 for high-resolution HLA class I typing of one allele or allele group (CPT 81381) and $177.25 for one locus (81380), and $7,776.00 for mRNA gene expression analysis of 15 genes in eye melanoma (81552). Labcorp bills its HLA-A∗02:01 test under CPT 81381 with a turnaround of 3 to 7 days, and the test has not been cleared or approved by the FDA. The DecisionDx-UM prognostic test, which Medicare covers for newly diagnosed uveal melanoma without evidence of metastasis, has a rate of $7,776 per test for 2026, and Castle Biosciences estimates a U.S. market of approximately $10 million. In the Ocumel Canada survey, 46.15% of respondents paid for their genetic testing, and some declined testing because of the cost. Strict compliance with DecisionDx-UM results was associated with a 50% reduction in surveillance procedures at two years and a 63% reduction at five years.

Darovasertib efficacy and safety

Summary: OptimUM-02 design and populations

OptimUM-02 (NCT05987332) is a phase 2/3, multi-arm, multi-stage, open-label study in HLA-A∗02:01-negative participants with metastatic uveal melanoma who have had no prior systemic therapy in the metastatic or advanced setting. The phase 2a dose optimization stage randomized participants 2:2:1 to darovasertib 300 mg BID plus crizotinib 200 mg BID, darovasertib 200 mg BID plus crizotinib, or investigator's choice; in December 2024 IDEAYA announced the Independent Data Monitoring Committee recommendation of a move-forward dose and the completion of Part 2a dose optimization. In the phase 2b and phase 3 portions, participants were randomized 2:1 to darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily or investigator's choice of pembrolizumab, ipilimumab plus nivolumab, or dacarbazine, stratified by baseline LDH and by investigator's choice of comparator treatment (ipilimumab plus nivolumab vs single-agent therapy). Treatment began with a 7-day run-in of darovasertib monotherapy before crizotinib was started. The primary endpoints are PFS by BICR per RECIST 1.1 in phase 2 and OS in phase 3, which IDEAYA states will be used to support a potential accelerated approval and full approval in the United States, respectively. The phase 2b analysis required 130 PFS events to detect a hazard ratio of 0.55 with 90% power (stratified log-rank test, 1-sided α of 2.5%), assuming a median PFS of 3 months in the control arm.

The full enrollment release reports 435 participants enrolled in December 2025, the annual report for 2025 reports 437, and the ClinicalTrials.gov record gives an estimated enrollment of 420. The primary analysis (data cutoff January 23, 2026) included an efficacy population of 313 participants, the intent-to-treat population of the phase 2b portion (210 darovasertib plus crizotinib; 103 investigator's choice). The ASCO 2026 abstract reports 338 participants who received at least one dose (safety population); the presentation reports safety populations of 239 participants treated with darovasertib 300 mg plus crizotinib 200 mg and 100 controls across phases 2a and 2b. Median follow-up was 7.4 months. In the control arm, 79 participants (76.7%) received ipilimumab plus nivolumab and 24 (23.3%) pembrolizumab, and none received dacarbazine; the topline release gives 78 (76%) and 25 (24%). In the combination and control arms, respectively, mean age was 61.1 and 61.5 years, 101 (48.1%) and 52 (50.5%) participants were female, 48 (22.9%) and 16 (15.5%) had ECOG performance status 1, 18 (8.6%) and 5 (4.9%) had a largest metastatic lesion of 8.1 cm or more, 127 (60.5%) and 65 (63.1%) had hepatic disease only, and 120 (57.1%) and 62 (60.2%) had baseline LDH at or below the ULN.

Summary: OptimUM-02 efficacy

At the January 23, 2026 data cutoff, the PFS analysis of the 313 participants was based on 159 events. Median PFS by BICR was 6.9 months (95% CI, 5.6 to 8.3) with darovasertib plus crizotinib and 3.1 months (95% CI, 1.8 to 4.2) with investigator's choice (hazard ratio 0.42; 95% CI, 0.30 to 0.59; p<0.0001), a 58% reduction in the risk of disease progression. By investigator assessment, median PFS was 6.7 months (95% CI, 5.6 to 8.2) and 2.7 months (95% CI, 1.7 to 4.1) (hazard ratio 0.36; 95% CI, 0.26 to 0.50).

The objective response rate (ORR) by BICR was 37.1% (78 of 210; 95% CI, 30.6 to 44.1) with darovasertib plus crizotinib and 5.8% (6 of 103; 95% CI, 2.2 to 12.3) with investigator's choice (odds ratio 10.8; 95% CI, 4.4 to 26.4), with five complete responses (2.4%) in the combination arm and none in the control arm. By investigator assessment, the ORR was 39.5% (83 of 210) and 1.9% (2 of 103). Median duration of response by BICR was 6.8 months (95% CI, 5.5 to 11.3) in the combination arm and not estimable in the control arm. The disease control rate (complete response, partial response, or stable disease for at least 12 weeks) by BICR was 73.3% (154 of 210) and 31.1% (32 of 103). Progressive disease was the best overall response by BICR in 13 participants (6.2%) and 29 participants (28.2%). As reported from the presentation, waterfall plots showed tumor reduction in “nearly 90% of patients” in the combination arm and “about 35% in the control arm”.

In the ESMO 2026 subgroup analysis (BICR), median PFS with darovasertib plus crizotinib and with control was 8.4 and 4.2 months with normal LDH, 5.7 and 1.8 months with LDH above the ULN and below 2 times the ULN, and 3.1 and 1.7 months with LDH 2 times the ULN or higher (n = 25 and 12); the corresponding ORRs were 46.7% and 8.1%, 27.7% and 3.4%, and 16.0% and 0%. Median PFS was 8.3 and 2.9 months with hepatic metastases, 4.9 and 2.8 months with hepatic and extrahepatic metastases, and 6.7 and 8.3 months with extrahepatic metastases only (n = 11 and 7). With a largest lesion of 8 cm or larger (n = 18 and 5), median PFS was 4.2 and 1.7 months and the ORR 11.1% and 0%. By control stratum, median PFS was 6.9 and 3.1 months in the ipilimumab plus nivolumab stratum and 5.8 and 2.8 months in the pembrolizumab or dacarbazine stratum. The poster states that for LDH 2 times the ULN or higher, target lesion 8 cm or larger, and extrahepatic-only metastases, the small numbers of participants gave wide 95% confidence intervals that included the null value.

OS, the phase 3 primary endpoint, was not mature at the primary analysis, and no OS estimate has been reported; the presentation reports “an early trend toward improved OS”, and IDEAYA states that the next OS update will be part of the prespecified interim analysis. The quarterly report for the first quarter of 2026 describes “a statistically significant improvement in the secondary endpoint of overall survival rate as assessed by blinded independent central review”.

Summary: OptimUM-02 safety

In the safety populations of the presentation (239 participants receiving darovasertib 300 mg plus crizotinib 200 mg and 100 receiving investigator's choice, phases 2a and 2b), treatment-related adverse events (TRAEs) of any grade occurred in 235 (98.3%) and 89 (89.0%) participants; the table of the most common TRAEs gives 88 (88.0%) for the control arm. Grade 3 or 4 TRAEs occurred in 97 (40.6%) and 37 (37.0%) participants, and treatment-related serious adverse events in 22 (9.2%) and 25 (25.0%); the ASCO 2026 abstract gives 9.2% and 25.3%. One grade 5 TRAE occurred in each arm (0.4% and 1.0%), and the abstract states that one treatment-related fatal adverse event occurred in each arm; the presentation describes the grade 5 serious adverse event in the combination arm as hepatic failure in a participant with extensive bulky liver metastases, considered unrelated by the sponsor, and the event in the control arm as gastrointestinal hemorrhage.

The most common TRAEs with darovasertib plus crizotinib were diarrhea (84.9%), nausea (74.9%), peripheral edema (66.9%), vomiting (49.8%), dermatitis acneiform (41.8%), fatigue (39.3%), and hypotension (33.1%); with investigator's choice, diarrhea (29.0%), increased alanine aminotransferase, increased aspartate aminotransferase, fatigue, and nausea (25.0% each), and pruritus (24.0%). Grade 3 or 4 TRAEs with the combination were mainly diarrhea (10.0%), syncope (7.1%), and hypotension (3.8%); with investigator's choice, increased alanine and aspartate aminotransferase (7.0% each), diarrhea (6.0%), hepatitis (5.0%), and colitis (4.0%). For treatment-emergent adverse events of any cause, the abstract reports diarrhea (89.5%), nausea (78.2%), peripheral edema (70.7%), and vomiting (53.6%) with the combination, and grade 3 or 4 diarrhea (10.9%) and syncope (7.9%). Hypotension and syncope were managed with hydration, holding blood pressure medications when appropriate, and the 7-day darovasertib run-in.

TRAEs led to withdrawal of darovasertib in 6 participants (2.5%), of crizotinib in 24 (10.0%), and of investigator's choice treatment in 19 (19.0%), and to dose reduction of darovasertib in 56 (23.4%) and of crizotinib in 63 (26.4%). The abstract reports adverse events leading to discontinuation and dose reduction of darovasertib in 3.8% and 23.8% and of crizotinib in 10.9% and 27.2%, and discontinuation in 19.2% of the control arm. Median relative dose intensities were 91.0% for darovasertib and 77.1% for crizotinib. Median duration of treatment was 6.31 months for darovasertib and crizotinib and 2.87, 2.56, and 2.79 months for pembrolizumab, ipilimumab, and nivolumab.

Summary: OptimUM-01 first-line cohort efficacy and safety

In the phase 2 expansion of OptimUM-01, an open-label phase 1/2 study enrolling participants irrespective of HLA status, 44 participants with no prior systemic therapy for metastatic uveal melanoma received darovasertib 300 mg twice a day plus crizotinib 200 mg twice a day (data cutoff May 28, 2025). Of these, 30 (68.2%) were HLA-A∗02:01-negative, 12 (27.3%) HLA-A∗02:01-positive, and 2 (4.5%) of unknown HLA status; 17 (38.6%) had ECOG performance status 1. Response was assessed by the investigator per RECIST version 1.1. In the 41 efficacy-evaluable participants, the confirmed ORR was 34.1% (14 of 41; 95% CI, 20.1 to 50.6), all partial responses; 23 (56.1%) had stable disease and 4 (9.8%) progressive disease. Median duration of response was 9.0 months (95% CI, 3.8 to 12.0) and median time to response 2.0 months. The disease control rate was 90.2% (37 of 41) at 8 weeks and 53.7% (22 of 41) at 26 weeks. With a median study follow-up of 25 months, median PFS was 7.0 months and median OS 21.1 months in the safety population, with PFS rates of 52% at 6 months and 28% at 12 months; the results section gives 95% CIs of 3.8 to 7.7 months for PFS and 12.5 to 27.1 months for OS, and the abstract gives 5.0 to 8.3 months and 11.9 to 20.7 months. In the 29 evaluable HLA-A∗02:01-negative participants, the ORR was 31.0% (9 of 29; 95% CI, 15.3 to 50.8), the disease control rate 86.2% (25 of 29), and median duration of response 9.03 months. In the 10 evaluable HLA-A∗02:01-positive participants, the subgroup table gives an ORR of 30.0% (3 of 10), and the discussion refers to “the observed ORR of 40%” in this subset. Among 20 participants with GNAQ/11 mutations reported from tumor tissue, 19 (95%) had a molecular response in cell-free DNA.

All 44 participants had at least one adverse event; grade 3 or higher treatment-emergent adverse events occurred in 23 (52.3%), serious adverse events in 9 (20.5%), TRAEs in 43 (97.7%), grade 3 or higher TRAEs in 12 (27.3%), and treatment-related serious adverse events in 4 (9.1%). The most common treatment-emergent adverse events were diarrhea (42 participants, 95.5%; the abstract gives 95.2%), nausea (84.1%), peripheral edema (61.4%), and vomiting (52.3%); the most common grade 3 or higher events were pulmonary embolism (9.1%) and iron deficiency anemia (6.8%). Two participants (4.5%) had grade 5 adverse events, one unrelated to study treatment and one deemed possibly related. Hypotension occurred in eight participants (18.3% in the text; 18.2% in the table), with one event of grade 3 or higher and no discontinuations for hypotension. Adverse events led to discontinuation in 3 participants (6.8%), and related adverse events led to dose reduction of darovasertib in 3 (6.8%) and of crizotinib in 4 (9.1%); 30 participants (68.2%) had at least one dose hold. Mean cumulative dose intensity was 84.9% for darovasertib and 80.0% for crizotinib, and a 2025 report of the same 44 participants (data cutoff 28 May 2025) gives median dose intensities of 92.6% and 88.0%.

Summary: OptimUM-01 HLA-A∗02:01-positive expansion

In the ESMO 2026 poster of the OptimUM-01 phase 2 expansion in HLA-A∗02:01-positive participants (data extract date March 23, 2026), 101 participants were treated with darovasertib plus crizotinib, with a median follow-up of 10.4 months for OS. Thirteen had no prior systemic therapy, 88 had received prior systemic therapy, and 15 received the combination in the second line after first-line tebentafusp; 22 (21.8%) had baseline LDH 2 times the ULN or higher. The confirmed ORR was 36.4% (4 of 11) in treatment-naive participants and 22.1% (19 of 86) overall, the disease control rate 90.9% (10 of 11) and 80.2% (69 of 86), median PFS 7.4 months (95% CI, 3.6 to 19.6) and 5.4 months (95% CI, 3.7 to 6.8), and median OS 27.1 months (95% CI, 8.9 to not evaluable) and 13.4 months (95% CI, 9.8 to 26.3). After prior tebentafusp, the confirmed ORR was 35.7% (5 of 14), median PFS 5.7 months, and median OS 12.1 months. TRAEs occurred in all 101 participants, grade 3 or higher TRAEs in 38 (37.6%), and treatment-related serious adverse events in 12 (11.9%); the most common TRAEs were diarrhea (82.2%), nausea (76.2%), peripheral edema (70.3%), and vomiting (57.4%). Adverse events led to discontinuation in 15 participants (14.9%), 9 of them treatment-related, and related adverse events led to dose reduction in 28 (27.7%).

Summary: single-agent LXS196 in the CLXS196X2101 phase 1 study

CLXS196X2101 (NCT02601378) was a Novartis-sponsored, first-in-human, multicentre, open-label phase 1 study of single-agent LXS196 (darovasertib) in metastatic uveal melanoma. Of 68 treated participants (56 in dose escalation, 12 in expansion), 59 (86.8%) had received prior systemic therapy and none had received prior tebentafusp. Doses ranged from 100 to 1000 mg once daily (n = 38) and 200 to 400 mg twice daily (n = 30). The maximum tolerated doses were 500 mg once daily and 400 mg twice daily, and the recommended dose for expansion was 300 mg twice daily. Dose-limiting toxicities occurred in 9 of 55 evaluable participants (16.4%), most commonly hypotension (n = 6; 10.9%).

Response (local RECIST v1.1 assessment) occurred in 6 of 66 evaluable participants (9.1%), with a median duration of response of 10.15 months; the results table, which includes 2 participants without post-baseline assessment in the denominator of 68, gives 1 complete response (1.5%) and 5 partial responses (7.4%), and the authors' comparison with AEB071 gives an ORR of 8.8%. At the recommended dose for expansion (18 participants), the ORR was 11.1% (95% CI, 1.4 to 34.7) and the disease control rate 77.8%. Median PFS was 3.6 months (95% CI, 3.5 to 5.4) in all participants and 3.7 months (95% CI, 2.1 to 5.4) at the recommended dose for expansion. Adverse events of any relationship occurred in 66 participants (97.1%) and were grade 3/4 in 29 (42.6%); the most frequent were nausea (70.6%), diarrhoea (54.4%), and vomiting (38.2%). Serious adverse events occurred in 14 participants (20.6%), most often hypotension (8.8%), and grade 3/4 hypotension occurred in 13.2% with once-daily and 3.3% with twice-daily dosing. The only adverse event leading to discontinuation was hepatic failure in a participant with known liver metastases.

Budget impact of Darovasertib

Summary

No price, wholesale acquisition cost, budget impact model, or cost-effectiveness analysis of darovasertib or of the darovasertib plus crizotinib regimen was found. In OptimUM-02, darovasertib 300 mg twice daily is given with crizotinib 200 mg twice daily; Pfizer lists the wholesale acquisition cost of XALKORI at $23,773.10 per package of 60 capsules for both the 200 mg and 250 mg strengths, accurate as of March 10, 2026. IDEAYA states that darovasertib, if approved for one or more designated indications, “may also be excluded from certain mandatory price negotiation provisions of the 2022 Inflation Reduction Act”. Median duration of treatment in OptimUM-02 was 6.31 months for darovasertib and crizotinib, against 2.87, 2.56, and 2.79 months for pembrolizumab, ipilimumab, and nivolumab in the control arm. Pembrolizumab is listed at $12,517.44 per dose given every 3 weeks (current as of September 2026), and tebentafusp (KIMMTRAK) at $22,050.00 per 100 mcg/0.5 mL vial (effective 1 July 2026). IDEAYA estimates approximately 1,500 newly diagnosed patients with metastatic uveal melanoma each year in the United States, and that HLA∗A2(-) patients represent “between 60-65% of all mUM patients”; other sources put HLA-A∗02:01-negative disease at 49% of individuals prescreened for a trial of tebentafusp and 42.9% of a U.S. real-world cohort.

Conclusions

Summary

Darovasertib is an investigational product, studied in combination with crizotinib in first-line HLA-A∗02:01-negative metastatic uveal melanoma. In the third quarter of 2026, IDEAYA submitted a new drug application for the combination under the FDA Real-Time Oncology Review (RTOR) program; no FDA acceptance of the application or action date was found. The FDA designated darovasertib an orphan drug for uveal melanoma in April 2022 and granted Fast Track designation to the combination in November 2022. IDEAYA states that the progression-free survival (PFS) data from OptimUM-02 may enable an accelerated approval filing, that overall survival (OS) data will support a potential full approval, and that an OS update is expected with the prespecified interim analysis in mid-2027.

OptimUM-02 is an open-label phase 2/3 trial in which 313 HLA-A∗02:01-negative participants without prior systemic therapy were randomized 2:1 to darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily or investigator's choice; ipilimumab plus nivolumab was selected for 79 control participants and pembrolizumab for 24, and none received dacarbazine. At a median follow-up of 7.4 months, median PFS by blinded independent central review (BICR) was 6.9 months with the combination and 3.1 months with investigator's choice (hazard ratio 0.42; 95% CI, 0.30 to 0.59), and the objective response rate by BICR was 37.1% (78 of 210) and 5.8% (6 of 103). Grade 3 or 4 treatment-related adverse events occurred in 40.6% (97 of 239) and 37.0% (37 of 100) of participants. Diarrhea was the most common treatment-related adverse event with the combination (203 participants, 84.9%); treatment-related adverse events led to withdrawal of darovasertib in 6 participants (2.5%) and of crizotinib in 24 (10.0%), and to dose reduction of darovasertib in 56 (23.4%) and of crizotinib in 63 (26.4%). OS data were immature at the cutoff, with an early trend favoring the combination, and no OS estimate has been reported; the quarterly report for the first quarter of 2026 describes a statistically significant improvement in the OS rate. Quality of life by the EORTC QLQ-C30 was a stated endpoint, and “quality-of-life data were not presented” at the ASCO 2026 presentation.

Evidence in HLA-A∗02:01-positive disease comes from OptimUM-01, an open-label, single-arm study. In its phase 2 expansion of 101 HLA-A∗02:01-positive participants, the confirmed objective response rate was 36.4% (4 of 11) in treatment-naive participants and 22.1% (19 of 86) overall, and 35.7% after prior tebentafusp; median PFS was 7.4 and 5.4 months in the treatment-naive and overall populations.

No price for darovasertib has been published. The regimen adds darovasertib to crizotinib, listed at $23,773.10 per 60 capsules. The first-line comparators in OptimUM-02 include pembrolizumab, listed at $12,517.44 per 3-week dose; tebentafusp, used in HLA-A∗02:01-positive disease, is listed at $22,050.00 per vial, and published cost-effectiveness analyses of tebentafusp report incremental cost-effectiveness ratios of $953,230 per QALY from a U.S. payer perspective and $728,513 per QALY gained at the sponsor-submitted price in the CADTH review.